Business services providers thrive by solving complex operational challenges for their clients, allowing them to focus on ...

The case involved a clinical trial of Akero's only product, a drug candidate aimed at treating a liver disease. It's the ...

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of ...

Equifax faces growth headwinds, premium valuation, and flat price action despite AI and cloud investments, with limited ...

Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with ...

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the ...

Summary Company's stock surged over 100% after positive 96-week results from its phase 2b SYMMETRY study using EFX to treat F4 compensated cirrhosis due to MASH patients. The company achieved a ...